We use our own and third party cookies to offer you our services, customize and analyze your browsing and show you advertising related to your preferences. By continuing to browse, we consider that you accept its use. You can change the settings and get more information in the
In the middle of the last century, it was believed that psoriasis was caused by an epidermal alteration, so the first treatments were directed at treating the disorder. Later, it was thought that skin inflammation was responsible for psoriasis, and non‑steroidal anti‑inflammatory drugs were administered to combat inflammatory proteins. In the late 1990s, the development of monoclonal antibodies marked a breakthrough in the study of various inflammatory diseases, including psoriasis. These antibodies allowed us to detect the cells involved in the manufacture of the proteins (interleukins) responsible for the inflammation in psoriasis, and it was found to be a systemic immune disease that did not only affect the skin. In the past two decades, a large number of interleukins have been discovered that are specifically related to psoriasis lesions, both cutaneous and articular, and drugs have been developed that act against these interleukins: the so‑called biological drugs.
The main lines of research are studies aimed at finding more effective and specific biological drugs that act against the newly discovered interleukins and which cause the fewest undesirable effects, such as infections. The purpose of the clinical trials being carried out in hospitals is to test the effectiveness and safety of biological therapies that affect interleukin 17 and interleukin 23.
Sorry this content wasn't helpful to you. Send us your comment and we will take it into account to continue improving.
Thanks for your help!
An error has occurred and we were unable to send your opinion, please try again later.
Substantiated information by:
Felipe Julio Ramirez GarciaRheumatologistRheumatology Department
Mercè Alsina GibertDermatologistDermatology Department
Paula Aguilera PeiroDermatologistDermatologist Department
Sara Gómez ArmayonesDermatologistDermatologist Department
Published: 22 February 2019
Updated: 22 February 2019
The donations that can be done through this webpage are exclusively for the benefit of Hospital Clínic of Barcelona through Fundació Clínic per a la Recerca Biomèdica and not for BBVA Foundation, entity that collaborates with the project of PortalClínic.
Receive the latest updates related to this content.
Thank you for subscribing!
If this is the first time you subscribe you will receive a confirmation email, check your inbox
An error occurred and we were unable to send your data, please try again later.
Subscribe to the Newsletter of Clínic
Receive the latest news from our institution directly to your email.
Thanks for your subscription!
We have received your information. Check your inbox, in a few moments you will receive a confirmation email.
An error has occurred and we have not been able to send your data, please try again later.
More about assistance and health
Join our job pool
Hospital Clínic de Barcelona looks for talented professionals to cover job openings on a regular basis.